Fig. 5: Combination of α-IL-33 or α-ST2L antibody enhances the anti-tumor effect of cisplatin in LLC allograft model. | Cell Death & Disease

Fig. 5: Combination of α-IL-33 or α-ST2L antibody enhances the anti-tumor effect of cisplatin in LLC allograft model.

From: IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer

Fig. 5

A Schematic representation of LLC allograft model and treatment strategy. B–D Tumor growth of LLC allografts treated with IgG, cisplatin, α-IL-33, α-ST2L, and cisplatin combined with α-IL-33 or α-ST2L (n = 4 per group). Tumor volume (B), tumor size (C) and tumor weight (D) were measured at the end of the experiment. Flow cytometric analysis of CD206+ ST2L+ M2 macrophages infiltration (E), M2 macrophages (CD206) to M1 (CD86) (M2/M1) ratio (F) and CD4+/CD25+/Foxp3+ regulatory T cells (Tregs) (G) in LLC tumors from each group. H, I Representative images of IF-immunohistochemistry (IF-IHC) staining of tumor sections from each group. Panels of CD206 macrophages (H) and Foxp3 Tregs (I) staining are shown as indicated. Nuclei were counterstained with DAPI (blue). J IL-33 IHC staining of tumor sections from each group. Scale bar, 20 μm. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test.

Back to article page